What the U.S. cannabis reclassification really means for issuers, advisors and capital markets - and why execution will matter more than optimism.
Dec 19, 2025
By: Bryce Szela, Chief Growth Officer, Odyssey
The U.S. government’s move to reclassify marijuana from Schedule I to Schedule III represents one of the most consequential federal shift for the cannabis industry in decades. It signals a new posture in Washington – one that places greater emphasis on medical legitimacy, expanded research and a potentially reduced level of friction for licenced producers that have long operated in a regulatory gray zone.
As Kim Rivers, CEO of Trulieve (an Odyssey client) told the Wall Street Journal this week, the move is “a meaningful step towards modernizing cannabis policy and allowing the regulated industry to continue to displace illicit operators.”
For cannabis companies (and the lawyers and advisors who guide them) the most useful way to interpret this development is not as a sweeping unlock, but as a defined set of changes bounded by equally important limits. History suggests the companies that benefit most from moments like this are not the loudest, but the most operationally prepared.
WHAT CHANGED THIS WEEK
Cannabis is now being formally recognized at the federal level as having accepted medical use. Schedule I is reserved for substances deemed to have no currently accepted medical use and a high potential for abuse. Schedule III, by contrast, includes substances with recognized medical applications and lower dependence risk.
That distinction matters because it influences how research is conducted, how regulators frame future policy and how institutions assess risk.
Tax dynamics may shift meaningfully, particularly for plant-touching operators. One of the most closely watched implications of reclassification is the potential impact on Section 280E of the U.S. tax code, which has historically limited the deductibility of ordinary business expenses for cannabis companies. While implementation details still matter, even partial relief could materially alter operating economics.
The capital-markets narrative is already changing. Markets tend to trade momentum ahead of fundamentals, and early reactions across public cannabis equities reflect renewed interest, increased deal chatter and a willingness among counterparties to re-engage.
WHAT HASN'T CHANGED
This is not federal legalization. Reclassification does not eliminate the state-by-state complexity that continues to define the U.S. cannabis market, nor does it remove all federal constraints overnight.
Regulatory and compliance rigor remains essential. As attention increases, so do expectations. Disclosure discipline, governance, internal controls and audit readiness remain non-negotiable, particularly for public issuers and those seeking institutional capital.
Execution risk remains the silent variable. In previous regulatory inflection points, companies that struggled were rarely undone by strategy. More often, they were challenged by operational gaps exposed at exactly the wrong moment.
WHAT THIS MEANS FOR CANNABIS ISSUERS
For U.S. cannabis issuers, the next phase is likely to bring increased transaction activity (including financings, M&A and restructurings) alongside heightened investor engagement and more complex shareholder dynamics. Companies with scalable, reliable infrastructure will be best positioned to respond quickly as opportunities emerge.
WHAT THIS MEANS FOR ATTORNEYS & ADVISORS
For trusted advisors, this moment is about managing acceleration without increasing risk. Clients will move faster, timelines will compress and expectations around execution will rise.
Advisors who can translate regulatory change into practical readiness will be indispensable as activity builds.
LESSONS FROM MARKETS THAT HAVE BEEN HERE BEFORE
Canada’s experience nearly a decade ago offers a useful reference point.
In the first major cannabis wave, optimism often arrived faster than infrastructure. The organizations that professionalized early, strengthening governance, shareholder management and execution discipline, navigated volatility far more effectively than those forced to react midstream.
THE ODYSSEY ADVANTAGE
Odyssey Trust Company has supported LPs and their advisors through precisely these types of inflection points when growth, complexity and regulatory change converge. The work is foundational rather than flashy: maintaining clean shareholder records, executing corporate actions accurately and supporting advisors so transactions proceed without unnecessary friction.
LOOKING AHEAD
For LPs, law firms and others advising cannabis companies, now is the right time to pressure-test readiness for a faster 2026. Regulatory momentum creates opportunity – but only for organizations ready to move quickly.
Connect with Odyssey to discuss how experienced transfer and trust support can help you scale confidently in 2026 and beyond.
